As SoHO Regulation discussions advance in the European Parliament and Council, it is more important than ever to recognise the contribution of all stakeholders to securing Europe’s supply of plasma and plasma-derived therapies within a resilient global plasma ecosystem.
Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX .
/PRNewswire/ Global biotechnology leader CSL (ASX: CSL) today announced that the European Commission has granted conditional marketing authorization (CMA).
Dublin, Ireland (PRWEB) November 07, 2022 Think Global Forum looks forward to welcoming our guests to our next live event, which will be held in Berlin on